CU20200084A7 - Derivados sustituidos de la carboxamida dihidropirazolo pirazina - Google Patents

Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Info

Publication number
CU20200084A7
CU20200084A7 CU2020000084A CU20200084A CU20200084A7 CU 20200084 A7 CU20200084 A7 CU 20200084A7 CU 2020000084 A CU2020000084 A CU 2020000084A CU 20200084 A CU20200084 A CU 20200084A CU 20200084 A7 CU20200084 A7 CU 20200084A7
Authority
CU
Cuba
Prior art keywords
dihydropirazolo
pirazine
carboxamide
substitute derivatives
substitute
Prior art date
Application number
CU2020000084A
Other languages
English (en)
Inventor
Thomas Brumby
Anja Buchmuller
Alexander Ehmann
Markus Follmann
Xiang Gao
Fabienne Gaugaz
Christoph Gerdes
Michael Gerisch
Nunez Eloisa Jimenez
Elisabeth Kerten
Dieter Lang
Lutz Lehmann
Niels Lindner
Steffen Muller
Hernández Nuria Ortega
Elisabeth Pook
Martina Schafer
Karl-Heinz Schlemmer
Georg Schmidt
Rudolf Schohe-Loop
Frank Sussmeier
Andreas Timmermann
Vivian Wang
Yafeng Wang
Stefanie Zimmermann
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20200084A7 publication Critical patent/CU20200084A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La invención se refiere a un compuesto de la fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>útil para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular de trastornos cardiovasculares, preferentemente de trastornos trombóticos o tromboembólicos y diabetes y también de trastornos urogenitales y oftálmicos.</p> <p>Se refiere también al método de preparación de dicho compuesto.</p>
CU2020000084A 2018-05-17 2019-05-10 Derivados sustituidos de la carboxamida dihidropirazolo pirazina CU20200084A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018087249 2018-05-17
PCT/EP2019/062005 WO2019219517A1 (en) 2018-05-17 2019-05-10 Substituted dihydropyrazolo pyrazine carboxamide derivatives

Publications (1)

Publication Number Publication Date
CU20200084A7 true CU20200084A7 (es) 2021-06-08

Family

ID=66625151

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000084A CU20200084A7 (es) 2018-05-17 2019-05-10 Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Country Status (25)

Country Link
US (1) US20220324865A1 (es)
EP (1) EP3793559A1 (es)
JP (1) JP2021523910A (es)
KR (1) KR20210013084A (es)
CN (1) CN112469412A (es)
AR (1) AR114906A1 (es)
AU (1) AU2019270142A1 (es)
BR (1) BR112020021612A2 (es)
CA (1) CA3100221A1 (es)
CL (1) CL2020002974A1 (es)
CO (1) CO2020014201A2 (es)
CR (1) CR20200554A (es)
CU (1) CU20200084A7 (es)
EA (1) EA202092779A1 (es)
EC (1) ECSP20072258A (es)
JO (1) JOP20200294A1 (es)
MA (1) MA52623A (es)
MX (1) MX2020012201A (es)
NI (1) NI202000083A (es)
PE (1) PE20210856A1 (es)
PH (1) PH12020551973A1 (es)
SG (1) SG11202010679SA (es)
TW (1) TW202012408A (es)
UY (1) UY38237A (es)
WO (1) WO2019219517A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
MA46191A (fr) 2016-09-09 2021-04-21 Incyte Corp Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
SMT202200294T1 (it) 2018-02-20 2022-11-18 Incyte Corp Derivati di n-(fenil)-2-(fenil)pirimidina-4-carbossammide e composti correlati come inibitori di hpk1 per trattare il cancro
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
WO2021094208A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094210A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
CN114236017B (zh) * 2022-02-23 2022-06-07 深圳市海滨制药有限公司 一种棕榈酸抗坏血酸酯及其杂质的检测方法
AU2024258924A1 (en) * 2023-04-19 2025-11-27 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101146540A (zh) * 2004-06-09 2008-03-19 默克公司 Hiv整合酶抑制剂
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
ES2387707T3 (es) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizinas y procedimientos de uso
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
CA2791100C (en) 2010-02-27 2018-01-30 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
SI2831077T1 (sl) 2012-03-28 2016-09-30 Merck Patent Gmbh Biciklični pirazinonski derivati
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
EP3055300B1 (en) * 2013-10-09 2018-03-07 Pfizer Inc Antagonists of prostaglandin ep3 receptor
CN105849109B (zh) * 2013-10-30 2018-01-23 拜耳制药股份公司 取代的氧代吡啶衍生物
WO2015129821A1 (ja) 2014-02-27 2015-09-03 国立大学法人東京大学 オートタキシン阻害活性を有する縮合ピラゾール誘導体
EP3215498B1 (en) 2014-11-03 2018-08-22 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
MY189118A (en) 2016-02-24 2022-01-26 Pfizer Pyrazolo[1,5-a]pyrazin-4-yl derivatives

Also Published As

Publication number Publication date
MA52623A (fr) 2021-03-24
UY38237A (es) 2019-11-29
CO2020014201A2 (es) 2021-03-08
CN112469412A (zh) 2021-03-09
EP3793559A1 (en) 2021-03-24
BR112020021612A2 (pt) 2021-01-26
MX2020012201A (es) 2021-01-29
CL2020002974A1 (es) 2021-03-05
JP2021523910A (ja) 2021-09-09
PH12020551973A1 (en) 2021-08-02
AR114906A1 (es) 2020-10-28
PE20210856A1 (es) 2021-05-18
SG11202010679SA (en) 2020-11-27
EA202092779A1 (ru) 2021-02-02
AU2019270142A1 (en) 2020-11-12
CA3100221A1 (en) 2019-11-21
CR20200554A (es) 2021-01-12
ECSP20072258A (es) 2020-12-31
WO2019219517A1 (en) 2019-11-21
NI202000083A (es) 2021-03-11
TW202012408A (zh) 2020-04-01
JOP20200294A1 (ar) 2020-11-17
US20220324865A1 (en) 2022-10-13
KR20210013084A (ko) 2021-02-03

Similar Documents

Publication Publication Date Title
CU20200084A7 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2020007265A (es) Derivados de rapamicina.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
EA201990833A1 (ru) Соединение пиридина
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
DOP2021000128A (es) Derivados de oxopiridina sustituidos
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
EA201792234A1 (ru) Новые соединения пиридиния
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2020010985A (es) Procedimiento para la preparacion de iloprost.
WO2016044433A3 (en) Metformin derivatives
WO2019102093A3 (fr) Procede de preparation du 1-chloro-3,3,3-trifluoropropene
TH1701002063A (th) ตัวยับยั้งแอลโดสเทอโรนซินเธส
EA201891690A1 (ru) Агонист fxr, представляющий собой производное стероидов
MX2016014692A (es) Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.